Ocugen Inc

$2.88 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Ocugen Inc

Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine is developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). It is developing OCU200, a novel biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.

Stock Analysis

last close $2.88
1-mo return 11.6%
3-mo return 37.1%
avg daily vol. 4.89M
52-week high 17.65
52-week low 1.67
market cap. $615M
forward pe -
annual div. -
roe -54.5%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 39.9%
baraka

Subscribe now for daily local and international financial news

Subscribe